Restoration of First-Phase Insulin Secretion by the Imidazoline Compound LY374284 in Pancreatic Islets of Diabetic db/db Mice

Annals of the New York Academy of Sciences

Volumn 1009, Issue , 2003, Pages 332-340

  Brenner, M B ^a   Gromada, J ^a   Efanov, A M ^a   Bokvist, K ^a   Mest, H J ^a  

^a Lilly Research Laboratories   (Germany)

Author keywords

db db mice; GLP 1; Imidazoline; Insulin secretion; Sulfonylureas

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM ION; DIAZOXIDE; GLUCAGON LIKE PEPTIDE; GLUCOSE; IMIDAZOLINE; INSULIN; LY 374284; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CALCIUM TRANSPORT; CELL ISOLATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOSOL; DEPOLARIZATION; DETERIORATION; DIABETES MELLITUS; DISEASE COURSE; GLUCOSE BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET;

EID: 1342284186     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1304.042     Document Type: Conference Paper

References (17)

1. PFEIFER, M.A., et al. 1981. Insulin secretion in diabetes mellitus. Am. J. Med. 70: 579-588.
2. STEINER, K.E., et al. 1982. The relative importance of first- and second-phase insulin secretion in countering the action of glucagon on glucose turnover in the conscious dog. Diabetes 31: 964-972.
3. MITRAKOU, A., et al. 1992. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326: 22-29.
4. ASHCROFT, F.M. 1996. Mechanisms of the glycaemic effects of sulfonylureas. Horm. Metab. Res. 28: 456-463.
5. PFEIFFER, E.F., et al. 1976. Hypoglycemia in diabetics. Horm. Metab. Res. Suppl. 6: 112-126.
6. SCHULZ, A. & A. HASSELBLATT. 1989. An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 340: 321-327.
7. PLANT, T.D. & J.C. HENQUIN. 1990. Phentolamine and yohimbine inhibit ATP-sensitive K+ channels in mouse pancreatic beta-cells. Br. J. Pharmacol. 101: 115-120.
8. EFANOV, A.M., et al. 2001. The novel imidazoline compound BL11282 potentiates glucose-induced insulin secretion in pancreatic beta-cells in the absence of modulation of K(ATP) channel activity. Diabetes 50: 797-802.
9. THORENS, B. 1992. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. U. S. A. 89: 8641-8645.
10. GROMADA, J., et al. 1995. Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release. FEBS Lett. 373: 182-186.
11. LACY, P.E. & M. KOSTIANOVSKY. 1967. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39.
12. PERDRIZET, G.A., et al. 1995. Albumin improves islet isolation: specific versus nonspecific effects. Transplant. Proc. 27: 3400-3402.
13. BRENNER, M. & H.J. MEST. 2003. Comparison of the insulin secretory kinetics from MIN6-pseudoislets and mouse islets. Naunyn Schmiedebergs Arch. Pharmacol. 367(Suppl 1): R73.
14. MEST, H.J., et al. 2001. Glucose-induced insulin secretion is potentiated by a new imidazoline compound. Naunyn Schmiedebergs Arch. Pharmacol. 364: 47-52.
15. HOY, M., et al. 2003. Imidazoline NNC77-0074 stimulates insulin secretion and inhibits glucagon release by control of Ca(2+)-dependent exocytosis in pancreatic alpha-and beta-cells. Eur. J. Pharmacol. 466: 213-221.
16. GEMBAL, M., et al. 1992. Evidence that glucose can control insulin release independently from its action on ATP-sensitive K+ channels in mouse B cells. J. Clin. Invest. 89: 1288-1295.
17. EFANOV, A.M., et al. 2002. Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rat. Am. J. Physiol. Endocrinol. Metab. 282: E117-E124.